on Andera Partners
Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom
Andera Partners announced today a €63 million Series A financing round for SciRhom, a Munich-based biopharmaceutical firm. The funds will drive SciRhom’s lead development program toward clinical proof-of-concept and broaden the therapeutic impact of its iRhom2 strategy. The round includes top-tier investors such as Kurma Partners, Hadean Ventures, MIG Capital, Wellington Partners, Bayern Kapital, and existing investors like High-Tech Gründerfonds and PhiFund Ventures.
SciRhom, specializing in autoimmune disorders, aims to address various autoimmune diseases by targeting iRhom2, a key regulator in autoimmune signaling pathways. Their lead candidate, SR-878, a monoclonal antibody, will enter clinical trials in the second half of 2024 to evaluate its safety and initial clinical activity.
The new investment will support SciRhom’s Phase 1 trials, which will commence in Austria. The company has shown positive preclinical results in rheumatoid arthritis and inflammatory bowel disease models. Founders and key partners emphasize SciRhom’s potential for transformative treatments in the autoimmune sector.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Andera Partners news